ID   OV-MZ-10
AC   CVCL_4003
DR   BTO; BTO_0004485
DR   Wikidata; Q54936835
RX   PubMed=7510115;
RX   PubMed=21559638;
CC   Doubling time: 27 hours (PubMed=7510115).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 11
//
RX   PubMed=7510115; DOI=10.1038/bjc.1994.78; PMCID=PMC1968867;
RA   Mobus V.J., Moll R., Gerharz C.-D., Kieback D.G., Weikel W.,
RA   Hoffmann G., Kreienberg R.;
RT   "Establishment of new ovarian and colon carcinoma cell lines:
RT   differentiation is only possible by cytokeratin analysis.";
RL   Br. J. Cancer 69:422-428(1994).
//
RX   PubMed=21559638; DOI=10.3892/ijo.5.4.753;
RA   Will C., Wilhelm O.G., Hohl S., Mobus V.J., Weidle U.H., Kreienberg R.,
RA   Janicke F., Schmitt M., Graeff H.;
RT   "Expression of urokinase-type plasminogen-activator (uPA) and its
RT   receptor (uPAR) in human ovarian-cancer cells and in-vitro invasion
RT   capacity.";
RL   Int. J. Oncol. 5:753-761(1994).
//